 DARTMOUTH, Nova Scotia CAMBRIDGE, Mass.--BUSINESS WIRE--IMV Inc. Nasdaq: IMV; TSX: IMV IMV or the Company, a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Friday, May 13, 2022, at 8:00 a.m. ET to discuss the companys 2022 first quarter financial and operational results. Financial analysts are invited to join the con 